Treatment of acute myocardial infarction in patients with ST segment elevation at onset of symptoms: The task force on the management of acute myocardial infarction of the European Society of Cardiology;Trattamento dell'infarto miocardico acuto in pazienti con sopraslivellamento del tratto ST all'esordio della sintomatologia: Task force sulla gestione dell'infarto miocardico acuto della European Society of Cardiology

Italian Heart Journal Supplement

Volumn 4, Issue 12, 2003, Pages 981-1016

  Van De Werf, Frans ^a   Ardissino, Diego ^a   Betriu, Amadeo ^a   Cokkinos, Dennis V ^a   Falk, Erling ^a   Fox, Keith A A ^a   Julian, Desmond ^a   Lengyel, Maria ^a   Neumann, Franz Josef ^a   Ruzyllo, Witold ^a   Thygesen, Christian ^a   Underwood, S Richard ^a   Vahanian, Alec ^a   Verheugt, Freek W A ^a   Wijns, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 57049126908     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (236)

1. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-13.
2. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 221: 1406-32.
3. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000; 83: 361-6.
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
5. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 1993; 22: 1141-54.
6. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699-708.
7. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101:570-80.
8. Armstrong A, Duncan B, Oliver MF, et al. Natural history of acute coronary heart attacks. A community study. Br Heart J 1972; 34: 67-80.
9. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-57.
10. Norris RM. Fatality outside hospital from acute coronary events in three British districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. BMJ 1998; 316: 1065-70.
11. Norris RM, Caughey DE, Mercer CJ, et al. Prognosis after myocardial infarction. Six-year follow-up. Br Heart J 1974; 36: 786-90.
12. de Vreede JJ, Gorgels AP, Verstraaten GM, et al. Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol 1991; 18: 698-706.
13. Hasdai D, Begar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 15: 1190-201.
14. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41 021 patients. GUSTO-I Investigators. Circulation 1995; 91: 1659-68.
15. Adams J, Trent R, Rawles J, on behalf of the GREAT Group. Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic therapy. BMJ 1993;307:409-13.
16. Grijseels EW, Deckers JW, Hoes AW, et al. Pre-hospital triage of patients with suspected acute myocardial infarction. Evaluation of previously developed algorithms and new proposals. Eur Heart J 1995; 16: 325-32.
17. Hauser AM, Gangadharan V, Ramos RG, et al. Sequence of mechanical, electrocardiographic and clinical effects of repeated coronary arterial occlusion in human beings: echocardiographic observation during coronary angioplasty. J Am Coll Cardiol 1985; 5: 193-7.
18. Lengyel M. The role of transesophageal echocardiography in the management of patients with acute and chronic pulmonary thromboembolism. Echocardiography 1995; 12: 359-66.
19. Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med 1997; 29: 116-25.
20. Heller GV, Stowers SA, Hendel RC, et al. Clinical value of acute rest technetium-99m tetrofosmin tomographic myocardial perfusion imaging in patients with acute chest pain and nondiagnostic electrocardiograms. J Am Coll Cardiol 1998; 31: 1011-7.
21. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2000; 102 (Suppl): 122-159.
22. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2000; 102 (Suppl): 182-1166.
23. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
25. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
26. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397-402.
27. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-5.
28. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
29. Neuhaus KL, Feuerer W, Jeep-Tebbe S, et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566-9.
30. A comparsion of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997; 337: 1118-23.
31. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 1995; 346: 329-36.
32. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337: 1124-30.
33. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999; 354:716-22.
34. Tebbe U, Michels R, Adgey J, et al, for the Comparison Trial of Saruplase and Streptokinase (COMPASS) Investigators. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. J Am Coll Cardiol 1998; 31: 487-93.
35. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-13.
36. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit of intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101:2239-46.
37. Berger AK, Radford MJ, Wang Y, et al. Thrombolytic therapy in older patients. J Am Coll Cardiol 2000; 36: 366-74.
38. White H. Thrombolytic therapy in the elderly. Lancet 2000; 356: 2028-30.
39. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383-9.
40. White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation 1998; 97: 1632-46.
41. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283: 2686-92.
42. Boersma H, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-5.
43. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92: 2811-8.
44. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523-8.
45. Maggioni AP, Franzosi MG, Santoro E, et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico II (GISSI-2) and the International Study Group. N Engl J Med 1992; 327: 1-6.
46. Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997; 95: 2508-16.
47. Boersma H, van der Vlugt MJ, Arnold AE, et al. Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. Eur Heart J 1996; 17: 64-75.
48. Zeymer U, Tebbe U, Essen R, et al. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Am Heart J 1999; 137: 34-8.
49. Bottiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001; 357: 1583-5.
50. Barbash GI, Birnbaum Y, Bogaerts K, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) and assessment of the safety of a new thrombolytic (ASSENT 2) studies. Circulation 2001; 103: 954-60.
51. Squire IB, Lawley W, Fletcher S, et al. Humoral and cellular responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J 1999; 20: 1245-52.
52. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671-7.
53. Antman EM, Giugliano CM, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720-32.
54. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788-94.
55. Brener SJ, Adgey JA, Zeymer U, et al. Combination low-dose t-PA and eptifibatide for acute myocardial infarction. Final results of the INTRO-AMI study. Circulation 2000; 102: 11-559.
56. Antman EM, Louwerenburg HVV, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105: 1642-9.
57. Ohman M. The FASTER Study, presented at the TCT Congress in Washington, DC, September 2002.
58. Topol EJ, for the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ilb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
59. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
60. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-6.
61. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med 1990; 323: 1433-7.
62. de Bono D, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-8.
63. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 22: 1615-22.
64. Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation 1991; 83: 1534-42.
65. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUS-TO-I trial. Circulation 1996; 93: 870-8.
66. Giugliano R, McCabe CH, Antman EM, et al. The Thrombolysis in Myocardial Infarction (TIMI) Investigators. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001; 141: 742-50.
67. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction - a pilot study: biochemical markers in acute coronary syndromes (BIO-MACS II). J Am Coll Cardiol 1999; 33: 627-33.
68. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997; 30: 962-9.
69. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648-52.
70. Wallentin L, Dellborg DM, Lindahl B, et al. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol 2001; 24 (Suppl): 112-114.
71. Simoons ML, Krzeminska-Pakula M, Alonso A, et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AM1-SK study. Eur Heart J 2002; 23: 1282-90.
72. Wallentin L. The ASSENT-3 PLUS trial. Presented at the 75th Scientific Sessions of the American Heart Association. Chicago, IL, November 2002.
73. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23:993-1003.
74. Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33: 1879-85.
75. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997; 96: 2155-61.
76. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lib Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
77. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.
78. White H, for the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-63.
79. Canto JG, Every NR, Magid DJ, et al. The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med 2000; 342: 1573-80.
80. The DANAMI-II Study. Presented at the Scientific Sessions of the American College of Cardiology. Atlanta, GA, March 2002.
81. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-9.
82. Grines CL, Browne KF, Marco J, et al, for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-9.
83. Gibbons RJ, Holmes DR, Reeder CS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Group. N Engl J Med 1993; 328:685-91.
84. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-4.
85. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341: 1413-9.
86. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein Ilb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000; 343: 385-91.
87. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO lib) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-8.
88. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093-8.
89. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341: 1949-56.
90. Stone GW, Grines CL, Cox DA, et al, for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
91. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991; 115: 173-7.
92. Brodie BR, Weintraub RA, Stuckey TD, et al. Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. Am J Cardiol 1991; 67: 7-12.
93. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581-8.
94. The TIMI Research Group. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. JAMA 1988; 260: 2849-58.
95. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; 1: 197-203.
96. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999; 34: 1954-62.
97. Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 1994; 90: 2280-4.
98. Califf RM, Topol EJ, Stack RS, et al. Evaluation of combination thrombolytic therapy and cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction-phase 5 randomized trial. TAMI Study Group. Circulation 1991; 83: 1543-56.
99. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999; 82: 426-31.
100. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000; 101: 101-8.
101. Montalescot G, Barragan P, Wittenberg O, et al, for the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators. Platelet glycoprotein Ilb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903.
102. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein Ilb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915-21.
103. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein Ilb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary, PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-41.
104. Nicod P, Gilpin E, Dittrich H, et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after myocardial infarction. Am J Cardiol 1988; 61:1165-71.
105. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-64.
106. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we Emergency Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-34.
107. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-2.
108. Lopez-Sendon J, Gonzalez A, Lopez de Sa E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and electrocardiographic criteria. J Am Coll Cardiol 1992; 19: 1145-53.
109. Pollak H, Diez W, Spiel R, et al. Early diagnosis of subacute free wall rupture complicating acute myocardial infarction. Eur Heart J 1993; 14:640-8.
110. Lengyel M, Pal M. Long-term survival of post-infarction free wall rupture without operation. Eur Heart J 1996; 17: 1769-70.
111. Lavie CJ, Gersh BJ. Mechanical and electrical complications of acute myocardial infarction. Mayo Clin Proc 1990; 65: 709-30.
112. Sanders RJ, Kern WH, Blount SG. Perforation of the interventricular septum complicating acute myocardial infarction. Am Heart J 1956; 51: 7-36.
113. Cummings RG, Califf R, Jones RN, et al. Correlates of survival in patients with postinfarction ventricular septal defect. Ann Thorac Surg 1989; 47: 824-30.
114. Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol 1992; 70: 147-51.
115. Topaz O, Taylor AL. Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management. Am J Med 1992; 93: 683-8.
116. Piwnica A. Update in surgical treatment of acute post-infarction ventricular septal defects and myocardial regurgitation. Eur J Cardiothorac Surg 1995; 9: 117-9.
117. Von Segesser LK, Siebenmann R, Schneider K, et al. Postinfarction ventricular septal defect. Surgical strategies and results. Thorac Cardiovasc Surg 1989; 37: 72-5.
118. Coma-Canella I, Gamallo C, Onsurbe PM, et al. Anatomic findings in acute papillary muscle necrosis. Am Heart J 1989; 118: 1188-92.
119. Nishimura RA, Schaff HV, Shub C, et al. Papillary muscle rupture complicating acute myocardial infarction: analysis of 17 patients. Am J Cardiol 1983; 51: 373-7.
120. Rankin JS, Feneley MP, Hickey MS, et al. A clinical comparison of mitral valve repair versus mitral valve replacement in ischemic mitral regurgitation. J Thorac Cardiovasc Surg 1988; 95: 165-77.
121. Cowan JC, Gardiner P, Reid DS, et al. Amiodarone in the management of atrial fibrillation complicating myocardial infarction. Br J Clin Pract Suppl 1986; 44: 155-63.
122. Lie KJ, Wellens HJ, Van Capelle FJ, et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind randomized study of 212 consecutive patients. N Engl J Med 1974; 29: 1324-6.
123. Koster RW, Dunning AJ. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. N Engl J Med 1985; 313: 1105-10.
124. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA 1988; 260: 1910-6.
125. Yusuf S, Lessem J, Jha P, et al. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J Hypertens 1993; 11 (Suppl 4): S61-S73.
126. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) IIB Study. Circulation 1991;83:422-37.
127. Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 2: 407-16.
128. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 32: 634-40.
129. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
130. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988; 1: 1088-92.
131. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1994; 343: 1115-22.
132. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium in 58 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345: 669-85.
133. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. Lancet 1994;344:91-7. 134.
134. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-7.
135. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac study (CCS-1). Lancet 1995; 345: 686-7.
136. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-84.
137. Pfeffer MA, Hennekens CH. When a question has an answer: rationale for our early termination of the HEART trial. Am J Cardiol 1995; 75: 1173-5.
138. Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991; 303: 1499-503.
139. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-8.
140. Antman E. The MAGIC trial. Presented at the XXIVth Scientific Sessions of the European Society of Cardiology. Berlin, September 2002.
141. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997; 96: 1152-6.
142. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994; 330: 1211-7.
143. Dell'Italia U, Starling MR, O'Rourke RA. Physical examination for exclusion of hemodynamically important right ventricular infarction. Ann Intern Med 1983; 99: 608-11.
144. Zeymer U, Neuhaus KL, Wegscheider K, et al. Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of Thrombolysis. J Am Coll Cardiol 1998; 32: 882-4.
145. Moreyra AE, Suh C, Porway MN, et al. Rapid hemodynamic improvement in right ventricular infarction after coronary angioplasty. Chest 1988; 94: 197-9.
146. Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-45.
147. Malmberg K. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-5.
148. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
149. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-27.
150. SWIFT trial of delayed elective intervention versus conservative treatment after thrombolysis with anistreplase in acute myocardial infarction.
151. Barbash GI, Roth A, Hod H, et al. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 538-45.
152. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997; 96: 748-55.
153. Kleiman NS, Califf RM. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. J Am Coll Cardiol 2000; 36: 310-25.
154. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists' Collaboration. Lancet 1994; 344: 563-70.
155. Mahmarian JJ, Mahmarian AC, Marks GF, et al. Role of adenosine thallium-201 tomography for defining long-term risk in patients after acute myocardial infarction. J Am Coll Cardiol 1995; 25: 1333-40.
156. Simoons ML, Vos J, Tijssen JG, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989; 14: 1609-15.
157. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992; 85: 1254-64.
158. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312-22.
159. Villella A, Maggioni AP, Villella M, et al. Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents: the GISSI-2 database. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1995; 346: 523-9.
160. De Feyter P, van Eenige MJ, Dighton DH, et al. Prognostic value of exercise testing, coronary angiography, and left ventriculography 6-8 weeks after myocardial infarction. Circulation 1982; 66: 527-36.
161. Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994; 90: 2687-94.
162. Anselmi M, Golia G, Cicoira M, et al. Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients. Am J Cardiol 1998; 81 (12A): 21G-28G.
163. Camici PG, Gropler RJ, Jones T, et al. The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. Eur Heart J 1996; 17: 25-34.
164. Bonow RO. Identification of viable myocardium. Circulation 1996; 94: 2674-80.
165. Pierard LA, De Landsheere CM, Berthe C, Rigo P, Kulbertus HE. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol 1990; 15: 1021-31.
166. Meza MF, Ramee S, Collins T, et al. Knowledge of perfusion and contractile reserve improves the predictive value of recovery of regional myocardial function post revascularization. A study using the combination of myocardial contrast echocardiography and dobutamine echocardiography. Circulation 1997; 96: 3459-65.
167. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-705.
168. Iliceto S, Marangelli V, Marchese A, et al. Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. Eur Heart J 1996; 17: 344-53.
169. Maes A, Van de Werf F, Nuyts J, et al. Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. Circulation 1995; 92: 2072-8.
170. Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
171. Working Group on Rehabilitation of the European Society of Cardiology. Long-term comprehensive care of cardiac patients. Recommendations by the Working Group on Rehabilitation of the European Society of Cardiology. Eur Heart J 1992; 13 (SupplC): 1-45.
172. Denollet J, Brutsaert D. Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. Circulation 1998; 97: 167-73.
173. Denollet J, Brutsaert D. Reducing emotional distress improves prognosis in coronary heart disease. Circulation 2001; 104: 2018-23.
174. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234-44.
175. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999; 99: 1173-82.
176. Dugmore LD, Tipson RJ, Phillips MH, et al. Changes in cardiorespiratory fitness, psychological well-being, quality of life, and vocational status following a 12 month cardiac exercise rehabilitation programme. Heart 1999; 81: 359-66.
177. Stable A, Mattsson E, Ryden L, et al. Improved physical fitness and quality of life following training of elderly patients after acute coronary events. A 1-year follow-up randomized controlled study. Eur Heart J 1999; 20: 1475-84.
178. Dorn J, Naughton J, Imamura D, et al. Results of a multicenter randomized clinical trial of exercise and long-term survival in myocardial infarction patients: the National Exercise and Heart Disease Project (NEHDP). Circulation 1999; 100: 1764-9.
179. Aberg A, Bergstrand R, Johansson S, et al. Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J 1983; 49: 416-22.
180. Taylor CB, Houston-Miller N, Killen JD, et al. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990; 113: 118-23.
181. De Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-85.
182. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-61.
183. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1999; 354: 447-55.
184. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 103-5.
185. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
186. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
187. Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. BMJ 1996; 313: 1429-31.
188. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study. Lancet 1997; 350: 389-96.
189. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282: 2058-67.
190. Fiore L, Ezekowitz MD, Brophy MT, et al, for the Combination Hemotherapy and Mortality Prevention Study Group. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study. Circulation 2002; 105: 557-63.
191. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus Coumadin versus aspirin alone in the prevention of reocclusion after fibronolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002; 106: 659-65.
192. van Es RF, Jonker JJ, Verheugt FW, et al. Antithrombotics in the Secondary Prevention of Events in Coronary Throm-bosis-2 (ASPECT-2) Research Group. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360: 109-13.
193. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-74.
194. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
195. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
196. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8-16.
197. The CAPRICORN Investigators. Effect of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-90.
198. The CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBfs-II): a randomised trial. Lancet 1999; 353:9-13.
199. The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
200. Olsson G, Oden A, Johansson L, et al. Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2 to 7 year follow-up. Eur Heart J 1988; 9: 365-72.
201. Pedersen TR. Six-year follow-up of the Norwegian multi-center study on timolol after acute myocardial infarction. N Engl J Med 1985; 313: 1055-8.
202. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990; 66: 779-85.
203. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-92.
204. Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis. Lancet 2000; 355: 1751-6.
205. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
206. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
207. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80-5.
208. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-6.
209. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9-12.
210. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure of left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81.
211. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomised trials. Circulation 1998; 97: 2202-12.
212. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
213. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
214. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
215. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-9.
216. Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999; 34: 106-12.
217. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
218. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
219. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-7.
220. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.
221. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
222. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.
223. Blohm M, Hartford M, Karlson BW, et al. A media campaign aiming at reducing delay times and increasing the use of ambulance in AMI. Am J Emerg Med 1994; 12: 315-8.
224. Belt N, Aroney G, Thompson P. Impact of a national educational campaign to reduce patient delay in possible heart attack. Aust N Z J Med 1993; 23: 157-61.
225. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early Action for Coronary Treatment (REACT) trial. JAMA 2000; 284: 60-7.
226. Bouten MJ, Simoons ML, Hartman JA, et al. Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction. Eur Heart J 1992; 13: 925-31.
227. GrijseeIs EW, Deckers JW, Hoes AW, et al. Pre-hospital triage of patients with suspected myocardial infarction. Evaluation of previously developed algorithms and new proposals. Eur Heart J 1995; 16: 325-327.
228. Weaver WD, Cerquiera M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211-6.
229. GREAT Group. Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners. Grampian region early anistreplase trial. BMJ 1992; 305: 548-53.
230. Colquhoun MC, Julian DG. Treatable arrhythmias in cardiac arrests seen outside hospital, (letter) Lancet 1992; 339: 1167.
231. Klootwijk P, Langer A, Meij S, et al. Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. Eur Heart J 1996; 17: 689-98.
232. Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31: 783-9.
233. Fox KAA, Cokkinos DV, Deckers JW, et al. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 2000; 21: 1440-9.
234. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001; 141: 190-9.
235. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891-4.
236. Newby LK, Califf RM, Guerci A, et al. Early discharge in the thrombolytic area: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll Cardiol 1996; 27: 625-32.